Why the study?
Do ACE inhibitors or ARBs reduce hospitalization for heart failure or cardiovascular mortality in patients with heart failure and preserved LVEF?
Do ACE inhibitors or ARBs reduce hospitalization for heart failure or cardiovascular mortality in patients with heart failure and preserved LVEF?
Answers are grounded in this paper and cite their sources.
In patients with HFpEF, ACE inhibitors or ARBs significantly reduce heart failure hospitalizations but do not improve cardiovascular mortality.
BACKGROUND: Heart failure (HF) with a preserved left ventricular (LV) ejection fraction (EF) is the leading cause of hospitalization after 65 years of age. Individual randomized trials have not shown benefits conferred by angiotensin-converting enzyme (ACE) inhibitors or angiotensin-II receptor blockers (ARB) in these patients. To overcome this limitation, we performed a meta-analysis of the randomized trials of ACE inhibitors or ARB in patients with HF and preserved LVEF. METHODS: Our search identified 4 randomized trials, comprising a total of 8152 patients, that investigated the effects of ACE inhibitors (n = 1), ARB (n = 2), or both treatments (n = 1). Risk ratios (RR) and 95% confidence intervals (CI) were calculated using a fixed-effect estimate method in the randomised trials. RESULTS: Compared with placebo or no treatment, treatment with ACE inhibition or ARB was associated with lower rates of hospitalization for HF (RR 0.90; 95% CI 0.81-0.99, P = .032), though not cardiovascular mortality (RR 1.01; 95% CI 0.90-1.13, P = 0.858). In 3 studies where these endpoints were combined, the 1-year incidence of cardiovascular death or hospitalization for HF was lowered by ACE inhibition or ARB (RR 0.74; 95% CI 0.58-0.94, P = .014). CONCLUSION: Compared with placebo, ACE inhibition or ARB significantly lowered risks of (a) hospitalization for HF and (b) the combined endpoint of cardiovascular mortality and hospitalization for HF at 1 year, in patients with HF and preserved LVEF. However, they have no significant effect on mortality during more prolonged follow-up; the width of the 95% confidence limits is compatible with a benefit as big as 10% or a hazard as large as 13%.
No takes yet. Share an insight, caveat, or question.
Meune et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: